Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Daihan Pharmaceutical Co., Ltd. is a leading South Korean manufacturer specializing in generic and specialty pharmaceuticals, with a strong presence in the domestic market and growing international sales, particularly in Southeast Asia. The company's competitive edge lies in its extensive R&D capabilities, allowing for a diverse product portfolio and rapid response to market demands.
Daihan generates revenue primarily through the production and sale of generic and specialty drugs, leveraging its strong R&D to develop cost-effective alternatives to branded medications. The company benefits from pricing power in the generic segment due to its established brand reputation and regulatory approvals.
Regulatory approvals for new generic drugs
Market share gains in Southeast Asia
Changes in healthcare policies affecting drug pricing
R&D pipeline advancements
Regulatory changes impacting drug approval processes
Technological disruption in drug manufacturing
Intensifying competition from other generic manufacturers
Potential for price erosion in the generic drug market
Liquidity risk due to high capital expenditures on R&D
Potential pension obligations if applicable
moderate - The pharmaceutical industry is somewhat insulated from economic downturns, but demand can be affected by consumer spending on healthcare.
Interest rates affect the company's cost of capital for R&D and expansion projects, potentially impacting future growth and valuation multiples.
minimal - The company has a zero debt-to-equity ratio, indicating strong liquidity and minimal reliance on external financing.
growth - Investors may be drawn to Daihan's potential for revenue growth through new product launches and market expansion.
low - The stock has historically shown lower volatility compared to its peers, attributed to its stable revenue streams.
